Recent Advances in Models of Immune-Mediated Drug-Induced Liver Injury

Farah Tasnim 1,2, Xiaozhong Huang 1,2,3, Christopher Zhe Wei Lee 1,4,5, Florent Ginhoux 1,4,6,7,8* and Hanry Yu 1,2,3,8,9,10*

OPEN ACCESS

Edited by: Eui Bae Jeung, Chungbuk National University, South Korea
Reviewed by: Mohammad Abdulkader Akbarsha, National College, Tiruchirappalli, India; Hartmut Jaeschke, University of Kansas Medical Center Research Institute, United States

*Correspondence:
Hanry Yu
hyu@ibn.a-star.edu.sg
Florent Ginhoux
florent_ginhoux@immunol.a-star.edu.sg

Specialty section:
This article was submitted to In Vitro Toxicology, a section of the journal Frontiers in Toxicology

Received: 12 September 2020
Accepted: 30 March 2021
Published: 27 April 2021

Citation:
Tasnim F, Huang X, Lee CZW, Ginhoux F and Yu H (2021) Recent Advances in Models of Immune-Mediated Drug-Induced Liver Injury. Front. Toxicol. 3:605392. doi: 10.3389/ftox.2021.605392

INTRODUCTION

Drug-induced liver injury (DILI) is a major cause of patient morbidity and mortality and remains a serious problem for clinicians, pharmaceutical industries and regulatory bodies (Hoofnagle and Björnsson, 2019). Although the complex mechanisms of DILI are not fully understood, both non-immune-mediated and immune-activated mechanisms have been proposed (Waddington et al., 2018). In contrast to non-immune-mediated DILI, prediction of immune-mediated DILI (im-DILI) has been more challenging due to intricate disease pathogenesis, limited knowledge of underlying mechanisms. This review summarizes in vivo and in vitro systems that have been used to model im-DILI. In particular, the review focuses on state-of-the-art in vitro human-based multicellular models which have been developed to supplement the use of in vivo models due to interspecies variation and increasing ethical concerns regarding animal use. Advantages of the co-cultures in maintaining hepatocyte functions and importantly, introducing heterotypic cell-cell interactions to mimic inflammatory hepatic microenvironment are discussed. Challenges regarding cell source and incorporation of different cells with physical cell-cell contact are outlined and potential solutions are proposed. It is likely that better understanding of the interplay of immune cells in liver models will allow for the development of more accurate systems to better predict hepatotoxicity and stratification of drugs that can cause immune-mediated effects.

Keywords: immune-mediated liver injury, co-culture, human iPSC, macrophages, Kupffer cells, hepatocytes, inflammation
mechanisms and lack of reliable models (Lee and Senior, 2005). The complexity of the system arises in part due to the liver being a unique immunological organ which harbors a rich, diverse array of complementary and interacting innate and adaptive immune cells (Adams et al., 2010; Waddington et al., 2018).

The resident innate immune cells in the liver include macrophages, called Kupffer cells (KCs), dendritic cells (DCs), neutrophils, natural killer (NK) cells and natural killer T (NKT) cells (Liaskou et al., 2012), while CD4+ and CD8+ T cells comprise the adaptive immune system (Waddington et al., 2018). In addition to these cells, the unique vascularization of the liver also allows for the recruitment of circulating leukocytes upon activation of relevant signaling pathways (Liaskou et al., 2012; Mak and Uetrecht, 2017). These immune cells are critical for establishing the balance between host defense against pathogens and tolerance to self- and harmless antigens. In the absence of external stimulus, this balance ensures optimal liver homeostasis. However, in the presence of an infection and/or inflammation, or upon exposure to certain compounds, the balance can be dysregulated, leading to immune cell activation (Krenkel et al., 2014; Waddington et al., 2018). Evolving studies suggest that the direct effects of drugs on hepatic cells might itself be an initiating factor to trigger such an immune response, as exemplified by the case of Acetaminophen (APAP)-mediated immune response (Krenkel et al., 2014). Briefly, KCs form the first line of defense and recognize invading pathogens or necrotic cells resulting from drug injury such as APAP overdose via danger-associated-molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs). KCs release cytokines [e.g., interleukin-6 (IL-6), tumor necrosis factor α (TNFα)] and chemokines (e.g., C-X-C motif ligand (CXCL)-1/3/8) upon activation, leading to acute inflammation marked by increased acute phase proteins such as C-reactive protein and complement components (Liaskou et al., 2012). In parallel, released cytokines lead to the upregulation of adhesion molecules in hepatic sinusoidal endothelial cells, while chemokines attract neutrophils and monocytes to the liver. Monocytes differentiate into tissue macrophages (MoMφ), and together with the originally resident macrophages (KCs) further release cytokines and factors that promote the survival of neutrophils and hence maintain inflammation. In addition, KC-activated (Krenkel et al., 2014) and DC-activated T-cells (Ogase et al., 2017) have been proposed to be important mediators of inflammation, although exact mechanisms have not been fully clarified yet.

Moreover, the contribution of immune cells is not only restricted to amplification of inflammation following the initial onset of immune activation. Roles of KCs, MoMφ and neutrophils have been reported in tissue repair and alleviation of injury (Shan and Ju, 2019). Specifically, KC and neutrophil death have been shown to promote tissue repair by switching MoMφ from pro- to anti-inflammatory states (Triantafyllou et al., 2018; Yang et al., 2019). These MoMφ in turn induce apoptosis of neutrophils, further resolving inflammation (Holt et al., 2008). Overall, immune cells have a critical role to play in both the augmentation and reduction of inflammation, and by extension in the progression and severity of im-DILI. Therefore, the key to predicting and preventing im-DILI is to first understand the complex interactions between immune cells and other parenchymal/non-parenchymal cells in the liver.

In vivo animal models have been used to model im-DILI (Shenton et al., 2004; Ng et al., 2012; Kuna et al., 2018; Uetrecht, 2019); however, treatment of animals with drugs that are known to cause im-DILI in humans do not cause consistent liver injury in animals, even at high doses (Uetrecht, 2019). Even when liver injury is observed, the characteristics are different from that of humans and possibly manifest through different mechanisms (Ng et al., 2012). In addition to the bottleneck of interspecies variation, animal models are expensive and there is increasing pressure toward reducing animal use in research. Owing to these challenges, significant efforts have been put into developing in vitro models to not necessarily replace, but rather to supplement in vivo animal models. Here, we describe important in vivo and in vitro systems that have been used to model im-DILI, with emphasis on the recent advances in multi-cellular in vitro systems comprising of immune cells to better recapitulate the complexity of the in vivo conditions, aiming to improve the current predictivity of in vitro liver models.

**ANIMAL MODELS**

In trying to understand DILI, animal models (especially mice and rat models) have long occupied center stage as the gold standard, becoming part of the regulatory requirement for drug development in almost all jurisdictions. The data gathered using these models has been invaluable, affording us a systemic view of the effects of drug absorption and metabolism, as it was through studying these systems that the role of the immune system in DILI came into the spotlight. Apart from the evident connection between hepatocyte death and the inflammatory response brought on by the DAMPs released during the apoptosis or necrosis of these cells (Martin-Murphy et al., 2010), there are also much more nuanced associations between DILI and the immune system that have been uncovered with the aid of depletion or knockout models.

For instance, KCs, the resident macrophages of the liver and the largest immune population as well, have been implicated in the progression of im-DILI in murine models. However, it is still unclear whether they play a protective or aggravating role. Mice that have been treated with Gadolinium Chloride (GdCl3) to inhibit KC activity prior to administration of APAP, appeared to be more resistant to injury, with lower levels of ALT observed after 8h as compared to control mice (Michael et al., 1999). Paradoxically, using a chlodronate-liposome based depletion approach seemed to have the opposing effect, as complete depletion of the KCs resulted in increased ALT serum levels, indicative of liver injury (Ju et al., 2002). However, these contrasting results might just be highlighting different aspects of macrophage biology, as GdCl3 does not deplete macrophages, but rather suppresses their activation and reactive oxygen species (ROS) production. The cross-talk between gut microbes and KCs further complicates the relationship between KCs and im-DILI. Lipopolysaccharide (LPS) has been identified as a possible contributing factor to liver injury, as it was observed that
mice that had been treated with GdCl3 were more resistant to alcohol-induced liver injury, similar to mice that have had their gut microbes depleted by antibiotics (Thurman et al., 1998). This reduction in liver injury was also seen in animals treated with anti-TNFα antibodies, hinting at the possible relationship between KC activation via LPS-induced TNFα and DILI severity. Later studies strengthened this connection, as mice that were given the broad spectrum antibiotic Trovafoxacin (TVX) alone did not develop DILI, while mice that received both LPS and TVX did (Shaw et al., 2007), similarly in a TNFα-dependent manner. KCs have also been shown to directly modulate the metabolic activity of hepatocytes (Odegaard et al., 2008), although the extent to which this contribution to DILI is still unknown and warrants further exploration. Equally intriguing is the possibility of macrophages participating directly in the metabolism of drugs, as several species of cytochrome P450 (CYP450) have been found to be expressed by macrophages in both rodents (Koop et al., 1991) and humans (Hodges et al., 2001).

The use of animal models has also revealed some role for NKT cells, and to a lesser extent NK cells, in the development of im-DILI. An initial study reported that NKT and NK cells contributed to liver injury in the case of APAP-induced toxicity in mice, and that depletion of these populations could significantly reduce the damages seen in these animals (Liu et al., 2004). This was later shown to be an artifact caused by the use of DMSO as the solvent for the APAP (Masson et al., 2008), which triggered the recruitment and activation of NKT and NK cells in the liver. In the absence of DMSO, NKT cells appeared to have a protective effect against APAP induced liver injury instead, with both CD1d−/− and Jα18−/− mice having elevated ALT serum levels as compared to the WT control (Martin-Murphy et al., 2013). However, this does not seem to be the case for all drugs though, as CD1d−/− mice were more resistant to the volatile anesthetic, halothane-induced liver damage, with a corresponding reduction in neutrophil infiltration as well (Cheng et al., 2010).

Although animal models have been immensely helpful, these contradictory results highlight the need for alternative models that can allow us to study specific cell-cell interactions with adjustable complexities to complement these in vivo systems.

IN VITRO MODELS

Soluble Factor-Driven Single Cultures in Combination With Inflammatory Mediators

Possibly with the aim to minimize complexity of the models, some studies have tried to mimic inflammatory effects by treating liver parenchymal cells (hepatocytes) with im-DILI-associated cytokines or conditioned media from immune cells instead of directly adding immune cells into the culture (Cosgrove et al., 2009, 2010; Melino et al., 2012; Saab, 2013) (Table 1, Figure 1). It has been demonstrated that conditioned media of THP-1 macrophages caused morphological and functional changes in hepatocytes (Melino et al., 2012). HepG2 cell line deployed in a high-throughput system with a combination of LPS/cytokine/drug co-treatment demonstrated inflammation-associated hepatotoxic potential with four im-DILI drugs (Saab, 2013). Primary rat hepatocytes (pRHs), human hepatocytes (pHs) and HepG2 utilized in a high throughput drug–cytokine co-treatment approach identified drug-cytokine hepatotoxicity synergies for multiple im-DILI-associated hepatotoxicants, largely potentiated by TNFα, interleukin-1α (IL-1α), and LPS (Cosgrove et al., 2009). A follow up study using this approach in combination with multiplex phosphoprotein signaling demonstrated the roles of different protein kinase-mediated signaling pathways in drug/cytokine synergy and hepatotoxicity (Cosgrove et al., 2010). These studies may be valuable for elucidating mechanisms in human cells due to their compatibility with high throughput, multiplexed measurements; however, the lack of direct immune cell interaction and crosstalk with hepatocytes remain unaddressed.

Conversely, studies have also tested the effects of drug-exposed hepatocyte media (Dragomir et al., 2011; Kelg et al., 2015; Ogese et al., 2017) or direct addition of hepatotoxicants on immune cells including DCs/T cells (Ogese et al., 2017) and KCs (Goto et al., 2015) without including hepatocytes in the culture (Table 1). Adding hepatotoxicants and LPS to rat KCs caused an increase in pro-inflammatory cytokine interleukin-1 beta (IL-1β) and decrease in anti-inflammatory cytokine IL-6 and interleukin-10 (IL-10) (Goto et al., 2015). However, TNFα secretion remained unchanged which is contradictory to in vivo evidence (Shaw et al., 2010; Monga, 2011). An increase in reactive oxygen intermediates and changes in pro-and anti-inflammatory cytokines when KCs were exposed to APAP or Diclofenac (DIC)-treated hepatocyte conditioned media have also been reported (Keogel et al., 2015). Of note, this particular study highlighted the wide donor-dependent variability in cytokine responses across different batches of KCs. Exosomes of drug-treated hepatocytes have been shown to be phagocytosed by monocyte-derived DCs and T cells activated using drug-specific hapten (Ogese et al., 2019). Another study by the same group showed that conditioned medium from hepatocytes treated with im-DILI-associated drugs activated DCs through High-mobility group box 1 protein (HMGB1) and other DAMP molecules, which in turn stimulated T cells (Ogese et al., 2017). HMGB1 was also suggested in a different study to serve as a DAMP in acetaminophen-treated hepatocyte-conditioned media which activated macrophages to produce cytotoxic and proinflammatory mediators known to be involved in hepatotoxicity (Dragomir et al., 2011). In addition, the role of DAMPs in inflammasome activation was tested using human hepatocarcinoma liver cell line, FLC-4, treated with amodiaquine and nevirapine (Kato and Uetrecht, 2017). Drug-treated FLC-4 conditioned media activated THP-1 macrophages, and while amodiaquine could activate THP-1 directly due to possible metabolism by THP-1, nevirapine did not as it needs to be metabolized primarily by hepatocytes prior to inflammasome activation (Kato and Uetrecht, 2017). Similar inflammasome activation through DAMPs with tolcopone and troglitazone (TGZ)-treated hepatocyte conditioned media have also been reported (Mak et al., 2018). Overall, these studies suggest that hepatotoxicants themselves or DAMP molecules released by apoptotic or necrotic hepatocytes after initial drug injury can be a key triggering factor for the activation of immune cells in the liver. However, the presence of hepatocytes in culture...
is still required to elucidate their complex crosstalk with immune cells, necessitating the need for more complex co-culture studies.

**Co-cultures of Animal Cells**

The majority of animal *in vitro* hepatocyte culture systems use pRHs, as they are easier to cryopreserve (Swales et al., 1996b) as well as maintain their metabolic functions better than mouse hepatocytes (pMHs) (Swales et al., 1996a). Recognizing the role of immune cells in the progression of DILI as seen in *in vivo* animal models, there has been some attempts to develop *in vitro* co-culture systems with both hepatocytes and immune cells. These approaches have mainly been restricted to monolayer cultures, although some inroads have also been made into 3 dimensional cultures containing other cell types such as stellate cells that better represent the *in vivo* environment (Kostadinova et al., 2013).

Given the abundance of macrophages within the liver, it is natural for the focus of immune-hepatocyte systems to be placed on KCs (Kurose et al., 1996; Milosevic et al., 1999; Tukov et al., 2006; Kostadinova et al., 2013; Bonzo et al., 2015; Rose et al., 2016) **(Table 2)**. These cultures typically involve sorting the hepatocyte and macrophage populations from freshly isolated livers, before putting them back into the same culture. From these cultures, it is evident that some of the inter-cellular interactions are recapitulated *in vitro*, as stimulating these co-cultures often result in greater responses than that of either cell type alone. For example, rat KCs that have been pre-treated with LPS increased Nitrate/Nitrite content in the co-culture 11-fold, as opposed to 7-fold in the case of KCs alone (Kostadinova et al., 2013).

| References          | Cells                  | 2D/3D | Duration | Stimuli (µg/ml) | im-DILI Compounds | Findings                                                                 | Disadvantages                      |
|---------------------|------------------------|-------|----------|-----------------|-------------------|-------------------------------------------------------------------------|------------------------------------|
| Melino et al.       | HepG2, HuH7, THP-1     | CM    | 24 h     | NA              | NA                | THP1 induce inflammatory responses in HepG2                            | No drug testing data.             |
| Saab (2013)         | HepG2                  | CM    | 24 h     | LPS (20), TNFα (0.1) | Chlorpromazine, TVX, Ranitidine, Sulindac, DIC, TGZ | Drug+/+effects within 100*Cmax; follow-up study unveiled the mechanisms Cosgrove et al., 2010. | Lack of immune cells. |
| Cosgrove et al.     | pHHs, HepG2, pRHs      | SC/monolayer | 12/24/48 h | LPS (10), TNFα (0.1), IFN (0.1), IL1α (0.02) | TVX, Ranitidine, nefazodone, nimesulide, telithromycin +90 | 19% of hepatotoxins showed cytokine synergy effects                                   | No drug-induced inflammatory response |
| Ogese et al.        | pHHs, drug-specific T cell, DCs | CM | 24 h | SMX-NO | Fluoxacinil, INH, amoxicillin | Fluoxacinil and SMX-NO prime T cell activity (HMG1). | / |
| Dragomir et al.     | pHHs, RAW264.7         | CM    | 24 h     | NA              | APAP              | Upregulation of pro-inflammatory genes in RAW264.7 via HMGB1 travel     | / |
| Kegel et al.        | pHHs, pHKCs            | CM    | 2 h      | NA              | APAP, DIC         | Drug+/+cytokine Donor-/matched                                       | Donor-variable cytokine response   |
| Goto et al.         | pRKCs                  | CM    | 24 h     | LPS (0.03)      | APAP, TVX, TGZ | Drug+/+cytokine, IL-6/IL-1β ratio↓                                     | No TV-induced TNFα observed        |
| Ogese et al.        | pHHs, drug-specific T cell, DCs | CM | 24 h | SMX-NO | Fluoxacinil, INH, amoxicillin | Drug-specific hapten activates T cell via exosome                      | / |
| Kato and Uetrecht   | FLC-4, THP1            | CM    | 7 d      | NA              | Amodiaquine, Nevirapine | DAMPs released from FLC-4 activate inflammasome from THP1             | / |
| Mak et al. (2018)   | FLC-4, THP1, J774A.1   | CM    | 7 d      | NA              | TGZ, tolcapone, entacapone | DAMPs released from FLC-4 activate inflammasome from THP1             | / |

**Table 1** | *In vitro* models comprising of soluble factors from conditioned media of hepatocytes and immune cells.

pRHs, primary rat hepatocytes; pMHs, primary mouse hepatocytes; pRKCs, primary rat Kupffer cells; pHKCs, primary human Kupffer cells; CM, conditioned media; SC, sandwich culture; DCs, dendritic cells; LPS, lipopolysaccharide; TNFα, tumor necrosis factor α; IFN, interferon; IL-1α, interleukine-1α; APAP, acetaminophen; TVX, trovafloxacin; DIC, diclofenac; TGZ, troglitazone; INH, isoniazid; SMX-NO, nitroso sulfamethoxazole; HGMB1, high-mobility group box 1 protein.
hepatocyte response to stress, in line with our understanding of them as integrative machines (Bleriot and Ginhoux, 2019).

The use of these hepatocyte/KC co-culture systems also helped to validate the role of KCs in the LPS/TNFα-induced TVX hepatotoxicity observed in the in vivo animal models. TVX toxicity in hepatocytes was much higher in the co-cultures and was exacerbated by the addition of LPS, while the addition of LPS and TVX to hepatocytes alone was much milder (Bonzo et al., 2015; Rose et al., 2016). However, pro-inflammatory cytokine, TNFα production did not increase in a dose-dependent manner upon LPS and TVX treatment as observed in vivo (Shaw et al., 2010). These observations are strongly indicative that

---

**TABLE 2 | Animal in vit re liver co-culture models comprising of hepatocytes and immune cells.**

| References          | Cells                  | 2D/3D | Duration | Stimuli (µg/ml) | im-DILI compounds | Findings                                                                 | Disadvantages                  |
|---------------------|------------------------|-------|----------|---------------|------------------|--------------------------------------------------------------------------|--------------------------------|
| Kurose et al. (1996) | pRHs, LPS-pRKCs        | 2D    | 2/4 h    | LPS (1)       |                  | LPS-pRKCs→TNFα and nitric oxide→Mt dysfunction in pRHs                   | No drug testing data          |
| Milosevic et al. (1999) | pRHs, pRKCs (1)      | Transwell | 48 h    | LPS (≤10)    |                  | LPS-induced cytokine in pRKCs reduced pRHs functions                     | No drug testing data          |
| Rose et al. (2016)   | pRHs, pRKCs (2.5)     | 2D    | 48 h    | LPS (1)       | APAP, TVX        | ↑ Cytotoxicity in co-cultures. Drugs altered levels of LPS-induced cytokines | No TVX-induced TNFα observed |
| Kostadinova et al. (2013) | pRHs, NPC (~1.5) | Transwell scaffold | 15 d | LPS (10)     | TGZ, TVX, APAP   | ↑ sensitivity in co-cultures; species-specific effect observed.           | Drug-induced inflammatory response not tested. |
| Tukov et al. (2006)  | pRHs, pRKCs (0.25)    | 2D    | 6 h     | LPS (0.0003 and 0.01) | APAP, chlorpromazine, monocrotaline | → ↑ TNFα, chlorpromazine, monocrotaline → ↓ TNFα | Only one drug tested |
| Bonzo et al. (2015)  | pRHs, pRKCs (2)       | 2D    | 24/48 h | LPS (1)       | TVX              | TVX→TNFα ↑ Ratio of TNFα/IL-6 ↓ IL-6 downregulated CYP in pRHs            | Only one drug tested |
| Goto et al. (2015)   | pRKCs                 | 2D    | 24 h    | LPS (0.03)    | APAP, TVX, TGZ   | Drug→cytokine, IL-6/IL-1β ratio ↓                                        | No TVX-induced TNFα observed |
| Poulsen et al. (2014)| RAW264.7              | 2D    | 12 h (TVX-2, LPS-10) | LPS (0.01)    | TVX<100 uM        | TVX-induced TNFα (ERK, JNK)                                              | Only one drug tested |

Numbers in parenthesis in the “cells” column indicate ratio of hepatocytes: immune cells. Absence of numbers indicate that the study didn’t specify the ratio of cell used. pRHs, primary rat hepatocytes; pRKCs, primary rat Kupffer cells; LPS, lipopolysaccharide; APAP, acetaminophen; TVX, trovafloxacin; TGZ, troglitazone; TNFα, tumor necrosis factor α; IL-6, interleukin-6; IL-1β, interleukin-1β; CYP, cytochrome P450.
although animal *in vitro* models are able to partially capture the cellular interactions involved in im-DILI, they are limited in recapitulating *in vivo* findings.

**Co-cultures of Human Cells**

**pHHs and pKCs Co-cultures**

The vast majority of human *in vitro* co-cultures have focused on co-cultures involving KCs, which is not surprising since they are hepatic resident macrophages comprising of 80–90% of total macrophages in the human body (Ma et al., 2017). Primary Kupffer cells (pKCs) and pHHs [the gold standard cell source for hepatocytes (Zeilinger et al., 2016)] have been co-cultured in a variety of culture formats including 2D (Sunman et al., 2004), micropatterned (Zinchenko et al., 2006; McVay et al., 2013; Nguyen et al., 2015), microtissue (Nguyen et al., 2016; Jiang et al., 2019; Kermanizadeh et al., 2019a) and microfluidic cultures (Long et al., 2016; Chen et al., 2017; Sarkar et al., 2017) in order to include inflammatory components to *in vitro* liver models (Table 3, Figure 1). In some of these studies, the authors used a ratio of 10:1 pHHs:pKCs (Long et al., 2016; Chen et al., 2017; Sarkar et al., 2017) in order to match KCs content of about 10% in the liver (Jones and Summerfield, 1989). However, due to enrichment of KCs in the periportal region under inflammatory conditions *in vivo*, a ratio of 2.5:1 pHHs:pKCs (Jaeschke, 2007) might be a better representation of inflammatory conditions *in vitro* (Sunman et al., 2004; Nguyen et al., 2015). In majority of these studies, the co-cultures were stimulated with LPS or cytokines or a combination of both (Sunman et al., 2004; Nguyen et al., 2015; Long et al., 2016; Chen et al., 2017; Sarkar et al., 2017) with the aim of analyzing the inflammatory response mediated by pKCs and their effects on specific pHHs metabolism. However, the findings of the studies were focused on specific cytokine-hepatocyte interactions such as IL-2 or IL-6 mediated downregulation of CYP3A4 in pHHs (Sunman et al., 2004; Long et al., 2016), an improvement of hepatocyte function and drug metabolism as a result of the co-culture (Zinchenko et al., 2006; Sarkar et al., 2017) and better mimicry of *in vivo* interactions with other organs such as the gut (Chen et al., 2017). To the best of our knowledge, there are only two reports on the immunemediated effects of a drug. One of them is a 3D InSight™ Human Liver Microtissue (InSphero) which was exposed to APAP (Jiang et al., 2019). APAP-induced production of interleukin-8 (IL-8) and IL-6 followed by a suppression of IL-6 in a dose dependent manner was reported. Transcriptomic analyses showed concurrent mitochondrial damage and oxidative stress responses. The results of this study must be interpreted carefully due to the high concentration of LPS used (10 µg/ml) (Jiang et al., 2019), which can cause significant toxicity even without the presence of the drug. The second one is a micropatterned triculture of pHHs, pKCs and fibroblasts (HepatoMune™, Hepregen/BioIVT) which demonstrated TVX-dependent TNFα increase at low concentrations followed by a decrease at higher concentrations (McVay et al., 2013), although consequent effects on pHHs were not tested. Unfortunately, only one drug was tested in both these models. The remaining culture systems mentioned above were not treated with drugs or compounds or even if they were treated with a single drug, immune-mediated effect of the drug was not tested. Hence the utility of these models in detecting immune-mediated DILI remains to be addressed.

**pHHs and Liver Non-parenchymal Cells (NPCs) Co-cultures**

Studies using other sources of immune cells other than pKCs include pHHs co-cultures with NPCs (Novik et al., 2010; Kostadinova et al., 2013; Messner et al., 2013; Esch et al., 2015; Bell et al., 2016). NPCs offer the advantage of testing effects of other hepatic cells such as stellate cells and endothelial cells in addition to KCs. Disadvantages include limited availability, cost, donor variability (Kermanizadeh et al., 2019a) and difficulty in controlling the ratio of pHHs: each NPC cell type; for example, increasing KCs amount to mimic *in vivo* inflammatory state would also increase the number of stellate cells, endothelial cells or fibroblasts in culture. Interestingly, a ratio of 1.5:1 pHHs: NPCs, was used for some of the studies (Kostadinova et al., 2013; Esch et al., 2015) with the intention to mimic 60% parenchymal and 40% non-parenchymal cells *in vivo*; however, this ratio doesn’t mimic *in vivo* inflammatory state in terms of KCs where pHHs:KCs ratio is about 2.5:1 (Jaeschke, 2007), nor is it clear whether *in vivo* content of other NPCs such as stellate cells (5–8%) is being mimicked (Yin et al., 2013). Of note is also the concentration of LPS used in these studies: 10–50 µg/ml which is significantly higher than concentrations used in most co-culture studies (50 ng/ml to 1 µg/ml) (Nguyen et al., 2015; Granitzny et al., 2017; Sarkar et al., 2017; Tasnim et al., 2019) and physiologically relevant concentrations (Desch et al., 1989). Irrespective of the culture conditions, the studies showed that pHHs functions could be stabilized for long-term cultures (>14 days) in the presence of NPCs, which was similar to findings in pHHs-pKCs co-cultures. Unlike pHHspKCs co-cultures, several drugs were tested in the pHHs-NPCs co-cultures: APAP (Kostadinova et al., 2013; Messner et al., 2013), TVX (Kostadinova et al., 2013; Messner et al., 2013), DIC (Messner et al., 2013; Bell et al., 2016) and TGZ (Kostadinova et al., 2013). In addition, Bell et al. treated their co-culture with Amiodarone, Boscentan, Fialuridine and Tolcapone (Bell et al., 2016). However, only the cytotoxic effects of the drugs were tested, showing improved sensitivity, i.e., detection of toxicity at lower concentrations in pHHs-NPCs co-cultures when compared to pHHs mono-cultures (Kostadinova et al., 2013; Messner et al., 2013; Bell et al., 2016). Immune-mediated effects of the drugs in the system were not tested.

**Hepatic Cell Lines and THP-1 Co-cultures**

Probably due to the cost and lack of availability of pKCs and NPCs, some studies have used alternative cell sources such as human hepatoblastoma cell line HepG2 and THP-1 monocytes/macrophages for the development of co-cultures (Granitzny et al., 2017; Wewering et al., 2017). The former reported increased cytotoxicity in THP-macrophage co-cultures, but not in THP-monocyte co-cultures in response to TGZ, TVX, DIC and Ketoconazole (KCL) in the presence of inflammatory stimulus: LPS and TNFα. The latter demonstrated co-culture specific induction of NRF2-mediated stress response and proinflammatory cytokines (CXCL8, TNFα and C-C motif ligand
| References | Cells | Culture format | Duration of culture | Stimuli (µg/ml) | im-DILI compounds | Key findings | Disadvantages |
|------------|-------|----------------|---------------------|----------------|-------------------|-------------|---------------|
| Sunman et al. (2004) | pHs, pKCs (2.5/10) | 2D | 72 h | IL1 (0.0002-0.02) IL6 (0.002-0.2) | / | Proinflammatory cytokine inhibits CYP3A; pKCs required for IL-2 effect on CYP3A. | No drug testing data. |
| Zinchenko et al. (2006) | pHs, pKCs (5/10) | MPCC/2D | 10 d | / | / | Superior pHs function in MPCC. | No drug testing data. |
| Nguyen et al. (2015) | pHs+3T3, pK Cs (2.5/10) | MPCC | <15 d | LPS (0.05) cytokines | / | Inflammatory stimulation systematically assessed | No drug testing data. |
| McVay et al. (2013) | pHs, pKCs | MPCC | 3/6 d | LPS (0.05) | TVX | TVX-induced TNFα (decrease > 200 µM) | Only one drug tested but using rat cells. |
| Kermanizadeh et al. (2019a) | pHs, pKCs | InSphero InSight MT | 7 d | / | nanoparticles | pKCs respond to pHs damage | Drug-induced inflammatory response not tested; only one drug tested. |
| Jiang et al. (2019) | pHs, pKCs | InSphero InSight MT | 24 h | LPS (10) | APAP (<10 mM) | ↑ Cytotoxicity in co-cultures APAP enhanced LPS-induced IL-6 (<5 mM); reduced IL-6 by 50% at 10 nM | Drug-induced inflammatory response not tested; only one drug tested. |
| Nguyen et al. (2016) | Liver tissue | Bioprinted | 7 d | / | TVX | Long-term functions sustained; LPS-independent mechanism of TVX toxicity. | Drug-induced inflammatory response not tested; only one drug tested. |
| Chen et al. (2017) | pHs, pKCs (10), intestinal cells | Microfluidic (LiverChip) | 3/15 d | LPS (0.002) | / | Mimic gut-liver axis; Long-term functions sustained. | No drug testing data. |
| Long et al. (2016) | pHs, pKCs (10) | Microfluidic (LiverChip) | <14 d | IL-6 (1) | Tocilizumab | IL6-CYP3A4 interaction tested. | No drug testing data. |
| Sarkar et al. (2017) | pHs, pKCs (10) | Microfluidic (LiverChip) | 48 h | LPS (1) | DIC (440 µM) | In-vivo like biotransformation of DIC; transcriptomics of co-culture | Drug-induced inflammatory response not tested; only one drug tested. |
| Messner et al. (2013) | pHs, NPC | Spheroid | 14d; <5 w | LPS (10) | APAP, TVX, DIC | ↑ Cytotoxicity in the presence of LPS | Drug-induced inflammatory response not tested. |
| Kostadinova et al. (2013) | pHs, NPC (~1.5) | Transwell scaffold | 15d | LPS (10) | TGZ, TVX, APAP (<10*Cmax | ↑ sensitivity in co-cultures; species-specific effect observed. | Drug-induced inflammatory response not tested. |
| Esch et al. (2015) | pHs, NPC (~1.5) | Scaffold Kostadinova et al., 2013 microfluidic | 14d | LPS (50) | / | pHH functions enhanced by flow; IL-8 production upon LPS. | No drug testing data. |
| Bell et al. (2016) | pHs, NPC (2) | Spin spheroid | 28 d | LPS (10) | DIC+4 more | ↑ sensitivity in co-cultures over time (w/o NPCs). | Drug testing results are based on pHH mono-culture. |
| Novik et al. (2010) | pHs, NPC (1) | HepREL® biochips | 24 h | / | / | pHH functions enhanced by flow. | No drug testing data. |
| Granitzny et al. (2017) | HepG2, THP-1 (2.5) | Transwell | 24/48 h | LPS (1), TNFα (0.1) TVX, DIC, TGZ, KCL (<20*Cmax) | TVX, DIC, macrophage, but not with THP-monocyte | ↑ Cytotoxicity in co-culture with THP-macrophage, but not with THP-monocyte | Drug-induced inflammatory response not tested. |
| Wewering et al. (2017) | HepG2, THP-1 | Transwell | 24 h | / | KCL | ↑ inflammation in co-culture only | Only one drug tested. |

(Continued)
(CCL)-3) upon treatment with KCL. A co-culture of the human hepatoma cell line Huh7 and THP-1 showed that TGZ exposure led to an increase in gene expression of pro-inflammatory cytokines and stress-related genes in both cell types (Edling et al., 2009). Although pro-inflammatory cytokines such as IL-1β was elevated in the co-culture, TNFα, a key pro-inflammatory cytokine was in fact downregulated. This might be due to the fact that cell lines are often not functionally similar to primary cells as exemplified by the differences in cytokine profiles of THP-1, KCs and human blood-derived primary macrophages following compound exposure (Kermanizadeh et al., 2019b).

Hepatic Cell Lines and NK Co-cultures

Most studies involving hepatic interactions with immune cells other than macrophages (e.g., NK cells, DCs and T cells) have been conducted with drug exposed-hepatocyte conditioned media (section Soluble Factor-Driven Single Cultures in Combination With Inflammatory Mediators). There are limited reports of direct co-cultures of hepatocytes and these immune cells. The only report of a direct co-culture is a study of human hepatocyte cell lines Huh7/HePG2 and peripheral blood mononuclear cell (PBMC)-derived NK cells which demonstrated enhanced NK cell activation and upregulation of NK cell ligands in Huh7/HePG2 after exposure to isoniazid (INH), KCL, Promethazine and Valproic acid (Fasbender et al., 2020). Increased cytotoxicity and interferon (IFN)-γ production were observed. This study demonstrated that, in addition to macrophages, NK cells can modulate im-DILI through direct interactions with hepatocytes.

Despite these studies contributing to significant progress in the field, most published studies were unfortunately limited to a single or handful of drugs and exposure scenarios. Hence, further work needs to be done for the establishment of a general im-DILI testing system that can be applied to structurally and mechanistically diverse im-DILI-associated compounds. One major challenge in performing such comprehensive studies is the lack of a source of relevant, functional cells that can be generated in large numbers. Cell lines (macrophages: mouse RAW264.7, human THP cell lines and hepatocytes: HepG2 and Huh7) can resolve the cell number issue but often do not represent the complex functions of primary cells (Kaur and Dufour, 2012). On the other hand, primary cells are expensive, show donor variability (Stoddart et al., 2012; Kegel et al., 2015; Kermanizadeh et al., 2019a), not easily accessible and cannot be expanded extensively in in vitro culture (Honegger, 1999).

### Induced Pluripotent Stem Cells Co-cultures

Generation of induced pluripotent stem cells (iPSCs)-derived cell types provide an attractive alternative due to their accessibility, renewability and scalability (Shi et al., 2017; Doss and Sachinidis, 2019). Although generation of iPSC-derived hepatocytes (iHeps) have been established over the past decade both by us (Tasnim et al., 2015, 2016; Mittal et al., 2016) and others (Hannoun et al., 2016; Maipa and Ndlovu, 2020), iPSC-derived macrophages (iMacs), especially iPSC-derived KCs (iKCs) and other immune cells generated from iPSCs (Trump et al., 2019) are still in their infancy (Lee et al., 2018). We have recently published the first report to generate iKCs from iPSC-derived macrophage precursors (preMΦ) by providing the preMΦ with hepatic cues (Tasnim et al., 2019). The transcriptomic profile of iKCs was distinct from bone marrow-derived macrophages, alveolar macrophages, non-liver macrophages as demonstrated by principal component analysis. iKCs were similar to pKCs in terms of marker expression and functions and could mimic pKCs in detecting hepatotoxicity of im-DILI associated drugs APAP and TVX when co-cultured with pHHs or iHeps (Tasnim et al., 2019). This is not trivial since iPSC-derived cells are often reported to be immature and have lower functions compared to their primary counterparts (Doss and Sachinidis, 2019; Volpato and Webber, 2020). We are currently working on two different aspects to improve and further validate our co-culture model.

The first aspect is a direct co-culture of iHeps and iMacs for providing iMacs with a hepatic niche in order to differentiate toward a hepatic lineage i.e., iKCs (in our previous study iKCs were generated using hepatic conditioned media and not a direct co-culture with hepatocytes (Tasnim et al., 2019). Other than providing direct cellular interactions, this system has the advantage of allowing generation of iKCs and iHeps from the

### TABLE 3 | Continued

| References | Cells | Culture format | Duration of culture | Stimuli (µg/ml) | im-DILI compounds | Key findings | Disadvantages |
|------------|-------|----------------|--------------------|-----------------|-------------------|--------------|--------------|
| Edling et al. (2009) | Huh7, THP-1 (2.5) | Transwell | 24 h | / | TGZ | ↑ Cytotoxicity and stress responses in co-culture | Drug-induced inflammatory response not tested; only one drug tested. |
| Fasbender et al. (2020) | Huh7, HepG2, pHHS; PBMCNK | 2D | Drug-24 h, add NK | / | INH, KCL, promethazine, valproic acid | Upregulation of NK cell ligand on hep exposed to drugs; ↑ Cytotoxicity in co-culture | HLA-unmatched co-culture |

The models can be broadly categorized into three different groups: (1) co-cultures of pHHs with pKCs (2) co-cultures of pHHs with NPCs (non-parenchymal liver cells), and (3) co-cultures of hepatic cell lines (HepG2 and Huh7) and macrophage cell line THP-1. Numbers in parenthesis in the “cells” column indicate ratio of hepatocytes: immune cells. In some studies, two different ratios were used, indicated by two numbers in the parenthesis. Absence of numbers indicate that the study didn’t specify the ratio of cell used. MPCC, micropatterned co-culture; MT, microtissue; LPS, lipopolysaccharide; IL-1, interleukin-1; IL-6, interleukin-6; TNFα, tumor necrosis factor α; APAP, acetaminophen; TVX, trovafloxacin; DIC, diclofenac; TGZ, troglitazone; INH, isoniazid; KCL, ketoconazole; NPCs, non-parenchymal cells.
same donor. Hepatocytes cultured with KCs (Tasnim et al., 2019) and T cells (Figueiredo et al., 2019) from different donors have shown activation of the respective immune cells. Alloreactivity could be reduced by silencing of HLA I on pHHs (Figueiredo et al., 2019). Donor-matched iKCs and iHeps developed by us would not require such additional measures to suppress immune reactions.

The second aspect we focus on is the application of the co-culture model to a diverse array and larger number of im-DILI associated drugs to validate if our model can stratify drugs based on their immune-mediated effects. Detailed cytokine production by iKCs upon treatment with each drug and their consequent effect on iHeps are being assayed. We are also analyzing correlation of the in vitro findings to clinical data to assess the physiological relevance of our model. Finally, such model might provide hints toward more sensitive hepatotoxicity endpoints as opposed to conventional cell viability assays.

TECHNICAL CHALLENGES IN ESTABLISHING CO-CULTURE

Despite the benefits of incorporating immune cells to investigate im-DILI, some key technical questions need to be addressed for co-culturing hepatocytes and immune cells: (1) How do we obtain a steady source of the appropriate immune cells, especially for human cultures? (2) For how long do functional co-cultures need to be maintained? (3) How do we balance the use of components essential for one cell type but harmful for the counterpart, such as serum and growth factor? (4) Are immune cells primed when being in contact to HLA-unmatched hepatocytes? (5) How well do in vitro cells recapitulate human pathophysiology?

Although similar difficulties also exist when trying to model hepatocyte only cultures, obtaining the appropriate human resident immune cells, KCs in this case, poses a unique challenge. Even though KCs are the largest immune population in the liver, they still only make up 10% of the liver, which makes obtaining and using primary KCs in co-culture screening models prohibitively expensive. Blood monocytes have been explored as a possible surrogate for KCs in co-culture models (Rennert et al., 2016), however with our current understanding of macrophage ontogeny (Ginhoux and Jung, 2014; Perdiguro et al., 2015), they might be an inadequate substitute. We now know that, as seen in the various murine fate mapping models (Hoeffel et al., 2015), human KCs are also initially seeded by non-hematopoietic stem cell derived embryonic macrophages (Bian et al., 2020). This has far-reaching consequences, as embryonic macrophages have been shown to maintain a distinct transcriptomic and epigenetic landscape in the murine models and are self-renewing well into adulthood under steady state conditions (Lavin et al., 2013). Thankfully, this is not an insurmountable challenge, as murine iMacs have been shown to be similar to embryonic yolk sac macrophages (Takata et al., 2017), and so human iMacs, especially in a hepatic environment, may prove to be a suitable KC surrogate in im-DILI co-culture models.

Developing a suitable KC surrogate is also dependent on overcoming a separate but related problem: defining human KC identity and their development and specification trajectories. Although the differentiation of murine KCs is well-studied (van de Laar et al., 2016), some of the markers used to distinguish KCs from macrophages are not applicable to humans. An example of this would be CLEC4F, which is considered a definitive KC marker in mice, but does not encode for a functional receptor in humans (Taylor et al., 2019). Furthermore, using a handful of surface markers to claim identity of cells raised in vitro can be misleading, as cells can downregulate or even lose expression of markers after prolong culture. This limitation is starting to be addressed by the increased adoption of high dimensional techniques such as bulk and single cell RNAseq and ATACseq, allowing for a more holistic view of macrophage development and tissue interactions. For instance, scRNAseq has allowed us to observe the step-wise transcriptomic changes that occur along KC specification in the human embryo (Bian et al., 2020), providing a reference framework for in vitro KC development. The large volume of data generated by these techniques also enables the use of powerful new tools such as CellPhoneDB to interrogate macrophage-tissue interactions (Efremova et al., 2020), which can help us to better understand injury mechanisms and identity therapeutic targets in future im-DILI models.

Long-term cultures are important for recapitulating the latency of im-DILI (Chalasani et al., 2015), which can be intermediate (1–8 weeks) or long (up to 12 months) (Liu and Kaplowitz, 2002). It is challenging to maintain the morphology and functions of hepatocytes on common 2D culture over extended periods (Richert et al., 2006). Long-term hepatocyte cultures have been maintained using more complex designs including 3D cultures (Mittal et al., 2016; Tasnim et al., 2016; Lauschke et al., 2019) and co-cultures [mainly with fibroblasts (March et al., 2015)]. Some of the long-term culture models which involve co-culture with immune cells have been described in section Co-cultures of Human Cells and Table 3. Hepatocyte functions were well-maintained for at least 1–2 weeks in both serum-containing (Zinchenko et al., 2006; Kostadinova et al., 2013) and serum-free conditions (Messner et al., 2013; Nguyen et al., 2015, 2016; Bell et al., 2016; Long et al., 2016) with the aid of supportive mechanical environment such as microtissue, microfluidics and spheroids. However, complex culture systems are not conducive to high throughput applications. When a less complex high-throughput model is required for long-term culture, optimization of medium conditions becomes necessary.

Medium is a critical factor for optimal cell function in vitro. This comprises of the basal medium and supplements including serum. Various immune cells share similar culture conditions: RPMI 1640 (basal medium) with 10% serum, sometimes supplemented with growth factors, is commonly used (Moore et al., 1967; Exley et al., 2010). Use of RPMI 1640 for hepatocyte culture has also been reported (Burdon and van Knippenberg, 1991) and was comparable to William’s E Medium (WEM) up to 6 days of culture (Nelson et al., 2013). Hence, RPMI 1640 (without serum) could be used for short-term co-culture of hepatocytes and immune cells. In agreement with this, Sana
et al. for instance, used RPMI 1640 for co-culture of hepatocytes and PBMCs and DCs for up to 96 h (Sana et al., 2014). The effect of RPMI 1640 or other suitable basal media (e.g., WEM) on long-term co-cultures of hepatocytes and immune cells needs to be addressed.

Compared to basal medium, the use of serum is more contradictory. On one hand, despite the heterogeneity of serum composition from different lots and origins, it is essential for in vitro expansion and for obtaining optimal cell functions of immune cells (Musson, 1983; Costello et al., 2000). On the other hand, serum is deleterious to human hepatocyte culture due to inhibition of important cell functions (Enat et al., 1984). In most cases, hepatocytes favor serum-free medium supplemented with insulin-transferin-selenium (ITS) and dexamethasone (Chard et al., 1987). We postulate that serum-free medium should be developed for co-cultures of hepatocytes and immune cells. A serum-free condition has been established for human KC culture by Tasnim et al. (2019). KCs were cultured with advanced DMEM plus Cocktail B™ (containing ITS) and in WEM plus Cocktail B™ when co-cultured with hepatocytes without functional compromise (Tasnim et al., 2019). Serum-free medium for immune cell cultures has been being development for decades, including AIM V™ and X-VIVO15™ (Medvec et al., 2018), but has yet to be tested for hepatocytes’ functions, especially for long term co-cultures.

Another important challenge which might often go unnoticed is the frequency of media change. On one hand, a high frequency of media change is not conducive to the interaction of hepatocytes and immune cells through soluble factors. On the other hand, hepatocytes are highly metabolic cells and hence require frequent media change (typically, hepatocyte media is changed daily). Therefore, co-culture conditions need to be tuned carefully in order to strike a delicate balance. To this effect, we have optimized a method to co-culture iMacs and iHeps for up to 1 week with ideal media change frequency and re-defined media supplement concentrations (unpublished data). It will be interesting to assess if these conditions work for longer time periods and other immune cell co-cultures.

Notably, glucocorticoids (GCs), such as dexamethasone, is essential to maintain hepatocytes’ functions particularly in extended period (Bailly-Maitre et al., 2001); however, they pose potent anti-inflammatory effects on immune cells, including macrophages (Werb, 1978; Rose et al., 2016), NK cells (Bush et al., 2012) and T cells (Ashwell et al., 2000). We also observed significant inhibitory effects of dexamethasone on pKCs and iKCs (data not shown). Conversely, low concentration of corticosterone (0.1 nM) was reported to enhance pro-inflammatory responses in rat PBMC (Lim et al., 2007). Despite such discrepancy, there are two options to resolve this: (1) Co-culture without dexamethasone which did not show any functional compromise in iHeps for short-term cultures (Tasnim et al., 2019) or (2) Selection of an appropriate GC to both maintain hepatocyte functions and retain cytokine production from KCs as demonstrated by Rose et al. (2016). Their results suggested that a less potent GC hydrocortisone might be used during the plating phase for the co-culture. However, whether these two options are applicable for long-term cultures needs to be systematically examined.

In addition, the need for HLA-matched cells in co-cultures should also be addressed. Due to limited accessibility to hepatocytes/immune cells, it is challenging to frequently obtain cells from the same donor. Many of the co-culture studies have to proceed with cells from different donors, indicating extremely low possibility of obtaining HLA-matched co-cultures. This might pose a challenge as HLA-unmatched co-cultures have shown to activate KCs (Long et al., 2016; Tasnim et al., 2019) and T cells (Figueiredo et al., 2019). Even though co-culture with transwell setup could attenuate the pre-activity of immune cells by reducing physical contact, it was also reported that HLA could travel through exosome to stimulate other immune cells (De Toro et al., 2015) or the paracrine factors secreted from immune cells could be sufficient for alloreactivity (Figueiredo et al., 2019; Tasnim et al., 2019). Strategies to reduce such activity include the use of the immune cells harboring the most frequent HLA class, or leveraging on donor-matched cells derived from human iPSCs.

Finally, careful consideration must be given to the interpretation of any functional readouts obtained from the stimulation of in vitro cells. These co-culture model systems are useful for the understanding of cell-to-cell interactions under specific defined conditions, and we should be careful not to overinterpret them in relation to complex human pathophysiology. As seen in a few of the studies mentioned previously, non-physiological concentrations of stimulants are sometimes used, partially in recognition of the decreased metabolic sensitivity of cells in culture, but often simply to obtain a response from these cells. One way around this issue might be the integration of in silico approaches with in vitro experiments. Using meta-analyses, possible pathways of im-DILI can be identified (Selvaraj et al., 2020), then experimentally tested using the relevant human in vitro systems. The results from these experiments can then be compared to clinical diagnoses and observations from human patients, giving a more holistic view of the adverse event.

**CONCLUSION AND FUTURE PERSPECTIVES**

Immune-mediated toxicity can involve many different cell types in various locations and can develop over a wide timeframe. A conceivable mechanism of im-DILI that has been proposed starts from reactive metabolite formation in the liver, followed by drug-modified proteins and release of DAMPs (Uetrecht, 2019). This in turn involves migration of antigen presenting cells to lymph nodes and spleen, where T cells are activated and return to the liver to mediate injury. It would be extremely challenging to duplicate this process in vitro; not only due to the complexity of the culture system involving hepatocytes, KCs, DCs and T cells, but also because the system has to be architecturally designed to mimic the sequence of events. Therefore, caution needs to be exercised when extrapolating the data obtained from in vitro studies to human pathophysiology. Specifically, it would not be appropriate to deduce immune-mediated injury mechanisms from the
results of these studies unless predictions obtained from the
data are consistent with characteristics of immune-mediated
toxicity in patients. In light of this, our recent work has
focused on identifying drugs that have clear immune-mediated
responses in patients (e.g., changes in specific cytokine levels
upon drug treatment) and validating if those specific changes
are recapitulated in our in vitro model (unpublished data).
In this manner, we could recapitulate certain elements of
immune-mediated toxicity in vitro. Nevertheless, further efforts
need to focus on improving the performance of in vitro
models so that they can reproduce more aspects of human
pathophysiology. In this regard, we postulate several strategies.
Systematic evaluation of conditions for long-term co-cultures
and development of microfluidic chip for temporal control of
intercellular interaction are encouraged. While classical studies
with primary cells and primary cell lines have helped to advance the
field immensely; we now have more options for cell sources
through establishment of iPSC-derived immune cells. Hence,
renewable and functional cell source of other immune cells
could be developed from human iPSC to overcome the low
accessibility of liver cells and to facilitate establishment of HLA-
matched co-cultures. Through this review, we highlight the gaps
in investigating im-DILI in vitro in order to encourage multi-
disciplinary efforts to improve the understanding and modeling of
im-DILI. Such developments will greatly enhance drug safety
assessment, especially in terms of predicting immune reactions
elicited by drugs.

REFERENCES

Adams, D. H., Ju, C., Ramaiah, S. K., Uetrecht, J., and Jaeschke, H. (2010). Mechanisms of immune-mediated liver injury. Toxcol. Sci. 115, 307–321. doi: 10.1039/tx0900749
Ashwell, J. D., Lu, F. W., and Vacchio, M. S. (2000). Glucocorticoids in T cell development and function. Annu. Rev. Immunol. 18, 309–345. doi: 10.1146/annurev.immunol.18.1.309
Bailly-Maitre, B., De Sousa, G., Boulukos, K., Gugenheim, J., and Rahmani, R. (2001). Dexamethasone inhibits spontaneous apoptosis in primary cultures of human and rat hepatocytes via Bcl-2 and Bcl-xL induction. Cell Death Differ. 8, 279–288. doi: 10.1038/sj.cdd.4400815
Bell, C. C., Hendriks, D. F., Moro, S. M., Ellis, E., Walsh, J., Renblom, A., et al. (2016). Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease. Sci. Rep. 6:25187. doi: 10.1038/srep25187
Berry, M. N., Edwards, A. M., and Barratt, G. J. (1991). "Monolayer culture of deapctylase and corepressor molecules. Cell. Immunol. 275, 80–89. doi: 10.1016/j.cellimm.2012.02.014
Chalasani, N., Bonkovsky, H. L., Fontana, R., Lee, W., Stolz, A., Talwalkar, J., et al. (2015). Features and outcomes of 899 patients with drug-induced liver injury: the DILI prospective study. Gastroenterology 148, 1340–1352.e1347. doi: 10.1053/j.gastro.2015.03.006
Chard, T., Work, T., and Work, E. (1987). Laboratory Techniques in Biochemistry and Molecular Biology. Amsterdam: Elsevier.
Chen, W. L., Edington, C., Suter, E., Yu, J., Velazquez, J. J., Velazquez, J. G., et al. (2017). Integrated gut/liver microphysiological systems elucidates inflammatory inter-tissue crosstalk. Biotechnol. Bioeng. 114, 2648–2659. doi: 10.1002/bit.26370
Cheng, L., You, Q., Yin, H., Holt, M. P., and Ju, C. (2010). Involvement of natural killer T cells in halothane-induced liver injury in mice. Biochem. Pharmacol. 80, 255–261. doi: 10.1016/j.bcp.2010.03.025
Cosgrove, B. D., Alexopoulos, L. G., Hang, T.-C., Hendriks, B. S., Sorger, P. K., Griffith, L. G., et al. (2010). Cytokine-associated drug toxicity in human hepatocytes is associated with signaling network dysregulation. Mol. Biosyst. 6, 1195–1206. doi: 10.1039/b926287c
Cosgrove, B. D., King, B. M., Hasan, M. A., Alexopoulos, L. G., Farazi, P. A., Hendriks, B. S., et al. (2009). Synergistic drug–cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxcol. Appl. Pharmacol. 237, 317–330. doi: 10.1016/j.taap.2009.04.002
Costello, E., Munoz, M., Buetti, E., Meylan, P., Diggelmann, H., and Thali, M. (2000). Gene transfer into stimulated and unstimulated T lymphocytes by HIV-1-derived lentiviral vectors. Gene Ther. 7, 596–604. doi: 10.1038/sj.gt.3301135
De Toro, J., Herschlik, L., Waldner, C., and Mongini, C. (2015). Emerging roles of exosomes in normal and pathological conditions: new insights for diagnosis and therapeutic applications. Front. Immunol. 6:203. doi: 10.3389/fimmu.2015.00203

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct and intellectual
contribution to the work, and approved it for publication.

FUNDING

The authors were supported by the Agency for Science,
Technology and Research (A*STAR) under its Industry
Alignment Fund-Pre-Positioning Programme (IAF-PP) (Grant
Number H18/01/a0/D14) as part of the A*STAR Innovations in
Food and Chemical Safety (IFCS) Programme as well as Institute
of Bioengineering and Nanotechnology (IBN) and Singapore
Immunology Network (SIgN) core funding. FG was a European
Molecular Biology Organization (EMBO) YIP awardee and
supported by the Singapore National Research Foundation
Senior Investigatorship (NRFI) NRF2016NRF-NRFI001-02.
XZH was a research scholar of the National University of
Singapore. CZWL was supported by the A*STAR Graduate
Scholarship.

ACKNOWLEDGMENTS

We also thank Dr. Yao Teng for her advice on fluidic device
illustration.

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct and intellectual
contribution to the work, and approved it for publication.

FUNDING

The authors were supported by the Agency for Science,
Technology and Research (A*STAR) under its Industry
Alignment Fund-Pre-Positioning Programme (IAF-PP) (Grant
Number H18/01/a0/D14) as part of the A*STAR Innovations in
Food and Chemical Safety (IFCS) Programme as well as Institute
of Bioengineering and Nanotechnology (IBN) and Singapore
Immunology Network (SIgN) core funding. FG was a European
Molecular Biology Organization (EMBO) YIP awardee and
supported by the Singapore National Research Foundation
Senior Investigatorship (NRFI) NRF2016NRF-NRFI001-02.
XZH was a research scholar of the National University of
Singapore. CZWL was supported by the A*STAR Graduate
Scholarship.

ACKNOWLEDGMENTS

We also thank Dr. Yao Teng for her advice on fluidic device
illustration.
of acetaminophen hepatotoxicity. Gastroenterology 127, 1760–1774. doi: 10.10353/gastro.2004.08.053
Long, T. J., Cosgrove, P., Dunn, R. T., Stolz, D. B., Hamadeh, H., Afsahi, C., et al. (2016). Modeling therapeutic antibody–small molecule drug-drug interactions using a three-dimensional perfusable human liver coculture platform. Drug Metab. Dispos. 44, 1940–1948. doi: 10.1124/dmd.116.011456
Ma, Y. Y., Yang, M. Q., He, Z. G., Wei, Q., and Li, J. Y. (2017). “The biological function of Kupffer cells in liver disease,” in Biology of Myelomonocytic Cells, ed A. Ghosh (London: IntechOpen), 2. doi: 10.5772/67673
Maepa, S. W., and Ndlovu, H. (2020). Advances in generating liver cells from pluripotent stem cells as a tool for modelling liver diseases. Stem Cells 38, 606–612. doi: 10.1002/stem.3154
Mak, A., Kato, R., Weston, K., Hayes, A., and Uetrecht, J. (2018). Editor’s highlight: Improved expansion and cryopreservation, but is strongly changed after hepatocyte plating. Drug Metab. Dispos. 46, 75–87. doi: 10.1124/dmd.116.011437
Mak, A., and Uetrecht, J. (2017). Immune mechanisms of idiosyncratic drug-induced liver injury. J. Clin. Transl. Res. 3, 145–156. doi: 10.18053/jctres.03.2017S1.001
March, S., Ramanan, V., Trehan, K., Ng, S., Galstian, A., Gural, N., et al. (2015). Micropatterned coculture of primary human hepatocytes and supportive cells for the study of hepatoprotic pathogens. Nat. Protoc. 10. doi: 10.1038/nprot.2015.128
Martin-Murphy, B. V., Kominsky, D. J., Orlicky, D. J., Donohue, T. M Jr., McVay, M., Kanchagar, C., Khetani, S. R., and Ukairo, O. (2013). Micropatterning of cytokine–drug interactions using micropatterned co-cultures of primary hepatocytes and Kupffer macrophages. Toxicol. Lett. 221:5150. doi: 10.1016/j.toxlet.2013.05.308
Medvec, A. R., Ecker, C., Kong, H., Winters, E. A., Glover, J., Varela-Rohena, A., et al. (2018). Improved expansion and in vivo function of patient T cells by a serum-free medium. Mol. Ther. Meth. Clin. Dev. 8, 65–74. doi: 10.1016/j.mitm.2017.11.001
Melino, M., Gadd, V. L., Walker, G. V., Skoien, R., Barrie, H. D., Jothishmani, D., et al. (2012). Macrophage secretory products induce an inflammatory phenotype in hepatocytes. World J. Gastroenterol. 18, 1732. doi: 10.3748/wjg.v18.i15.1732
Messner, S., Agarkova, I., Moritz, W., and Kelm, J. (2013). Multi-cell type pluripotent stem cells as a tool for modelling liver diseases. Stem Cells 31, 606–612. doi: 10.1002/stem.3154
Nelson, L. J., Treskes, P., Howie, A. F., Walker, S. W., Hayes, P. C., and Plevris, J. N. (2013). Profiling the impact of medium formulation on morphology and functionality of primary hepatocytes in vitro. Sci. Rep. 3, 27375. doi: 10.1038/srep02735
Ng, W., Lobach, A. R., Zhu, X., Chen, X., Liu, F., Metushi, I. G., et al. (2012). Animal models of idiosyncratic drug reactions. Adv. Drug. Metab. 63, 81–135. doi: 10.1016/S0978-07-398339-8.00003-3
Nguyen, D. G., Funk, J., Robbincs, J. B., Crogan-Grundy, C., Presnell, S. C., Singer, T., et al. (2016). Bioprinted 3D primary liver tissues allow assessment of organ-level response to clinical drug induced toxicity in vitro. PLoS ONE 11:e0158674. doi: 10.1371/journal.pone.0158674
Nguyen, T. V., Ukairo, O., Khetani, S. R., McVay, M., Kanchagar, C., Seghezzi, W., et al. (2015). Establishment of a hepatocyte-Kupffer cell coculture model for assessment of proinflammatory cytokine effects on metabolizing enzymes and drug transporters. Drug Metab. Dispos. 43, 774–785. doi: 10.1124/dmd.114.11061.3137
Novik, E., Maguire, T. J., Chao, P., Cheng, K., and Yarmush, M. L. (2010). A microfluidic hepatic coculture platform for cell-based drug metabolism studies. Biochem. Pharmacol. 79, 1036–1044. doi: 10.1016/j.bcp.2009.11.010
Odegao, J. I., Ricardo-Gonzalez, R. R., Red Eagle, A., Vats, D., Morel, C. R., Geforoth, M. H., et al. (2008). Alternative (M2) activation of Kupffer cells by PPARα ameliorates obesity-induced insulin resistance. Cell Metab. 7, 496–507. doi: 10.1016/cmet.2008.04.003
Ogese, M. O., Faulkner, L., Jenkins, R. E., French, N. S., Coppie, I. M., Antoine, D. J., et al. (2017). Characterization of drug-specific signaling between primary human hepatocytes and immune cells. Toxicol. Sci. 158, 76–89. doi: 10.1093/txs/tox069
Ogese, M. O., Jenkins, R. E., Adair, K., Tailor, A., Meng, X., Faulkner, L., et al. (2019). Exosomal transport of hepatocyte-derived drug-modified proteins to the immune system. Hepatology 70, 1732–1749. doi: 10.1002/hep.30701
Perdiguero, E. G., Klapproth, K., Schulz, C., Busch, K., Azzoni, E., Crozet, L., et al. (2015). Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature 518, 547–551. doi: 10.1038/nature14399
Poulsen, K. L., Albee, R. P., Ganey, P. E., and Roth, R. A. (2014). Truvafloxacin potentiation of lipopolysaccharide-induced tumor necrosis factor release factor from RAW 267.4 cells requires extracellular signal-regulated kinase and c-Jun-N-terminal kinase. J. Pharmacol. Exp. Ther. 349, 185–191. doi: 10.1124/jpet.113.12175
Rennert, K., Otto, P., Funke, H., Huber, O., Tomaso, H., and Mosig, A. S. (2016). A human macrophage – hepatocyte co-culture model for comparative studies of infection and replication of Francisella tularensis LVS strain and subspecies holarctica and mediastica. BMC Microbiol. 16:2. doi: 10.1186/s12866-015-0621-3
Richert, L., Liguori, M. J., Abadie, C., Heyd, B., Manton, J., Halkis, N., et al. (2006). Gene expression in human hepatocytes in suspension after isolation is similar to the liver of origin, is not affected by hepatocyte cold storage and cryopreservation, but is strongly changed after hepatocyte plating. Drug Metab. Dispos. 34, 870–879. doi: 10.1124/dmd.105.007708
Rose, K. A., Holman, N. S., Green, A. M., Andersen, M. E., and LeCluyse, E. L. (2016). Co-culture of hepatocytes and Kupffer cells as an in vitro model of inflammation and drug-induced hepatotoxicity. J. Pharmac. Sci. 105, 950–964. doi: 10.1016/S0022-3549(15)00192-6
Saab, L. (2013). Development of a cellular predictive model of inflammation associated idiopathic drug-induced hepatotoxicity and investigation of its underlying cellular and molecular mechanisms (Doctoral dissertation). Strasbourg: Université de Strasbourg.
Sana, G., Lombard, C., Vosters, O., Jazouli, N., Andre, F., Stephenne, X., et al. (2014). Adult human hepatocytes promote CD4+ T-cell hypersensitivity via interleukin-10-producing allogeneic dendritic cells. Cell Transplant. 23, 1127–1142. doi: 10.3727/096368913X666412
Sarkar, U., Ravindra, K. C., Large, E., Young, C. L., Rivera-Burgos, D., Yu, J., et al. (2017). Integrated assessment of diclofenac biotransformation, pharmacokinetics, and omics-based toxicity in a three-dimensional human liver/intestine co-culture system. Drug Metab. Dispos. 45, 855–866. doi: 10.1124/dmd.116.074095
Selvaraj, S., Oh, J.-H., and Borlak, J. (2020). An adverse outcome pathway for immune-mediated and allergic hepatitis: a case study with the NSAID diclofenac. Arch. Toxicol. 94, 2733–2748. doi: 10.1007/s00204-020-02767-6
Shan, Z., and Ju, C. (2019). Hepatic macrophages in drug-induced liver injury. *Liver Res.* 3, 170–175. doi: 10.1016/j.livres.2019.11.002

Shaw, P. J., Ganey, P. E., and Roth, R. A. (2010). Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. *Toxicol. Sci.* 118, 7–18. doi: 10.1093/toxsci/kfp018

Shaw, P. J., Hopfensperger, M. J., Ganey, P. E., and Roth, R. A. (2007). Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha. *Toxicol. Sci.* 100, 259–266. doi: 10.1093/toxsci/kfm218

Shenton, J. M., Chen, J., and Uetrecht, J. P. (2004). Animal models of idiosyncratic drug reactions. *Chem. Biol.* 15, 53–70. doi: 10.1016/j.chembi.2004.09.001

Shi, Y., Inoue, H., Wu, J. C., and Caldwell, J. (2017). Cryopreservation of rat and mouse hepatocytes. *Eur. Cell. Mater.* 24, i–ii. doi: 10.22203/ecm.v024a00

Sunman, J. A., Hawke, R. L., LeCluyse, E. L., and Kashuba, A. D. (2004). Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. *Drug Metab. Dispos.* 32, 359–363. doi: 10.1124/dmd.32.3.359

Swales, N. J., Johnson, T., and Caldwell, J. (1996a). Cryopreservation of rat and mouse hepatocytes. II. Assessment of metabolic capacity using testosterone metabolism. *Drug Metab. Dispos.* 24, 1224–1230.

Swales, N. J., Luong, C., and Caldwell, J. (1996b). Cryopreservation of rat and mouse hepatocytes. I. Comparative viability studies. *Drug Metab. Dispos.* 24, 1218–1223.

Takata, K., Kozaki, T., Lee, C. Z. W., Thion, M. S., Otsuka, M., Lim, S., et al. (2017). Induced-pluripotent-stem-cell-derived primitive macrophages provide a platform for modeling tissue-resident macrophage differentiation and function. *Immunity* 47, 183–198. doi: 10.1016/j.immuni.2017.06.017

Tasnim, F., Phan, D., Toh, Y.-C., and Yu, H. (2015). Cost-effective differentiation of hepatocyte-like cells from human pluripotent stem cells using small molecules. *Biomaterials* 70, 115–125. doi: 10.1016/j.biomaterials.2015.08.002

Tasnim, F., Toh, Y.-C., Qu, Y., Li, H. H., Phan, D., Narmada, B. C., et al. (2016). Functionally enhanced human stem cell derived hepatocytes in galactosylated cellulose sponges for hepatotoxicity testing. *Mol. Pharm.* 13, 1947–1957. doi: 10.1021/acs.molpharmaceut.6b00119

Tasnim, F., Xing, J., Huang, X., Mo, S., Wei, X., Tan, M.-H., et al. (2019). Generation of mature Kupffer cells from human induced pluripotent stem cells. *Biomaterials* 192, 377–391. doi: 10.1016/j.biomaterials.2018.11.016

Taylor, M. E., Snelling, T., Smith, D. F., and Drickamer, K. (2019). Absence of a human ortholog of rodent Kupffer cell galactose-binding receptor encoded by the CLEC4f gene. *Glycobiology* 29, 332–345. doi: 10.1093/glycob/cwy113

Thurman, R. G., Bradford, B. U., Iimuro, Y., Knecht, K. T., Arteel, G. E., Yin, M., et al. (1998). The role of gut-derived bacterial toxins and free radicals in alcohol-induced liver injury. *J. Gastroenterol. Hepatol.* 13, S39–S50. doi: 10.1111/j.1440-1746.1998.tb04839.x

Triantafyllou, E., Pop, O. T., Possamai, L. A., Wilhelm, A., Liaskou, E., Singanayagam, A., et al. (2018). MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure. *Gut* 67, 333–347. doi: 10.1136/gutjnl-2016-313615

Trump, L. R., Nayak, R. C., Singh, A. K., Embresh, S., Wellendorf, A. M., Lutzko, C. M., et al. (2019). Neutrophils derived from genetically modified human induced pluripotent stem cells circulate and phagocytose bacteria in vivo. *Stem Cell Trans. Med.* 8, 557–567. doi: 10.1002/sctm.18-0255

Tukov, F. F., Maddox, J. F., Amacher, D. E., Bobrowski, W. F., Roth, R. A., and Ganey, P. E. (2006). Modeling inflammation–drug interactions in vitro: a rat Kupffer cell-hepatocyte coculture system. *Toxicol. In Vitro* 20, 1488–1499. doi: 10.1016/j.tiv.2006.04.005

Uetrecht, J. (2019). Mechanistic studies of idiosyncratic DILI: clinical implications. *Front. Pharmacol.* 10:837. doi: 10.3389/fphar.2019.00837

van de Laar, L., Saelens, W., De Prijck, S., Martens, L., Scott, C. L., Van Isterdael, G., et al. (2016). Yolk sac macrophages, fetal liver, and adult monocytes can colonize an empty niche and develop into functional tissue-resident macrophages. *Immunity* 44, 755–768. doi: 10.1016/j.immuni.2016.02.017

Volpato, V., and Webber, C. (2020). Addressing variability in iPSC-derived models of human disease: guidelines to promote reproducibility. *Dis. Model. Mech.* 13:dmm042317. doi: 10.1242/dmm.042317

Waddington, J. C., Meng, X., Naisbitt, D. J., and Park, B. K. (2018). Immune drug-induced liver disease and drugs. *Curr. Opin. Toxicol.* 10, 46–53. doi: 10.1016/j.cotox.2017.12.006

Werb, Z. (1978). Biochemical actions of glucocorticoids on macrophages in culture. Specific inhibition of elastase, collagenase, and plasminogen activator secretion and effects on other metabolic functions. *J. Exp. Med.* 147, 1695–1712. doi: 10.1084/jem.147.6.1695

Wewering, F., Jouy, F., Wissenbach, D. K., Gebauer, S., Blüher, M., Gebhardt, R., et al. (2017). Characterization of chemical-induced sterile inflammation in vitro: application of the model compound ketoconazole in a human hepatic co-culture system. *Arch. Toxicol.* 91, 799–810. doi: 10.1007/s00204-016-1868-y

Yang, W., Tao, Y., Wu, Y., Zhao, X., Ye, W., Zhao, D., et al. (2019). Neutrophils promote the development of reparative macrophages mediated by ROS to orchestrate liver repair. *Nat. Commun.* 10, 1–14. doi: 10.1038/s41467-019-09046-8

Yin, C., Evason, K. J., Asahina, K., and Stainier, D. Y. (2013). Hepaticstellate cells in liver development, regeneration, and cancer. *J. Clin. Invest.* 123, 1902–1910. doi: 10.1172/JCI66369

Zeilinger, K., Freyer, N., Damm, G., Seehofer, D., and Knöspel, F. (2016). Cell sources for in vitro human liver cell culture models. *Exp. Biol. Med.* 241, 1684–1698. doi: 10.1177/1535370216657448

Zinchenko, Y. S., Schrum, L. W., Clemens, M., and Coger, R. N. (2006). Hepatocyte and Kupffer cells co-cultured on micropatterned surfaces to optimize hepatocyte function. *Tissue Eng.* 12, 751–761. doi: 10.1089/tm.2006.12.751

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Tasnim, Huang, Lee, Ginhoux and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.